Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01554124

Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis (NeoMero-2)

Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Probable and Confirmed Meningitis: A European Multicenter Phase I-II Trial

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Meningitis

Interventions Meropenem

Updated 5 times since 2017 Last updated: Feb 12, 2015 Started: Feb 28, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Meningitis, this trial is completed. The trial is conducted by Chiesi Farmaceutici S.p.A. and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.
PENTA Foundation

Data source: PENTA Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom